Michael Daly, NP
Acute Care · Statesboro, GANPI 1659748077
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 237 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,649, 2.5 times the $668 reported in 2021. Among acute care clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 237 payments — averaging $21.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- Neurocrine Biosciences, Inc.$902
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$809
- AbbVie$468
- Vanda Pharmaceuticals Inc.$463
- Alkermes, Inc.$419
- plus $872 from 6 others
What the payments were for
- Food & beverage$4,90197%
- Education$1383%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 49 | $1,106 |
| Neurocrine Biosciences, Inc. | 37 | $902 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 36 | $809 |
| AbbVie | 36 | $468 |
| Vanda Pharmaceuticals Inc. | 16 | $463 |
| Alkermes, Inc. | 26 | $419 |
| Axsome Therapeutics, Inc. | 9 | $256 |
| Teva Pharmaceuticals USA, Inc. | 11 | $254 |
| E.r. Squibb & Sons, L.L.C. | 8 | $196 |
| Johnson & Johnson | 7 | $115 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $29 |
| Lundbeck LLC | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,040 in reported general payments places this provider in the 95th percentile of 679 acute care providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 31 | $250,895 |
| Austedo XrDeutetrabenazine | 16 | $75,366 |
| VraylarCariprazine Hcl | 44 | $60,901 |
| Abilify MaintenaAripiprazole | 21 | $60,391 |
| Invega SustennaPaliperidone Palmitate | 23 | $54,958 |
| CaplytaLumateperone Tosylate | 30 | $54,693 |
| EliquisApixaban | 13 | $7,152 |
| Fluphenazine Hcl | 15 | $2,358 |
| Divalproex Sodium ErDivalproex Sodium | 46 | $2,071 |
| Ziprasidone Hcl | 66 | $1,657 |
| Aripiprazole | 82 | $1,617 |
| Clonazepam | 138 | $1,542 |
| Haloperidol Decanoate | 22 | $1,452 |
| Quetiapine Fumarate | 171 | $1,376 |
| Benztropine Mesylate | 108 | $1,192 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $902 | $250,89531 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $254 | $75,36616 claims |
| AbbVieVraylar | $468 | $60,90144 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,106 | $60,39121 claims |
| Johnson & JohnsonInvega Sustenna | $115 | $54,95823 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $809 | $54,69330 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 679 acute care providers in Georgia.
Other acute care in Statesboro
- Darryl TurnerRinggold$21K
- Bryce CowgillCumming$16K
- Stacy CreelSavannah$15K
- Susan BeitzellAthens$13K
- Crystal KuhnCumming$12K
- Mark ClarkGainesville$10K
- Sarah WymanAtlanta$10K
- Jeffrey DillerAustell$10K
- Ayeshia PowellAtlanta$10K
- Mitzi WilliamsGainesville$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.